Jetex Annual Review Dubai, United Arab Emirates, Dec. 29, 2022 (GLOBE NEWSWIRE) — The business aviation industry is currently going through the biggest transition in history, accelerated by the digitalisation, accessibility, and the exceptional travel conveniences that it offers against the backdrop of a gradual recovery from the health crisis.

Highlights Include New Product Launches, Numerous Industry Partnerships, and a Ramping Up of Trade Surveillance Services New York, NY, Dec. 29, 2022 (GLOBE NEWSWIRE) — Abel Noser Holdings, the market leader in institutional trade analytics and agency-only trading solutions, has many notable achievements to look back on this year as

SHANGHAI, China, Dec. 29, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces the online publication in New England Journal (NEJM) of the Phase 3 trial (NCT05341609)

UI GreenMetric 2022: Luiss among the top 20 most sustainable universities ROME, Dec. 28, 2022 (GLOBE NEWSWIRE) — Luiss continues to climb the UI GreenMetric 2022 ranking of the world’s most sustainable universities, taking 19th place globally among the 1,050 participating universities and 2nd place in Italy. Since its first entry in 2018, Luiss has […]

London, Dec. 27, 2022 (GLOBE NEWSWIRE) — The much-anticipated changes to St Kitts and Nevis’ Citizenship by Investment Programme have been announced today by the country’s recently appointed Citizenship by Investment Unit Head, Michael Martin. Setting a bold and new tone for the industry as a whole, St Kitts and

BITPOINT Latam is continuing to expand its services in Latin America, a market that is seeing rapid growth in cryptocurrency adoption. BITPOINT’s executives have stated that their recent focus on the Japanese market is part of their plan to increase education and commercial activity in the cryptocurrency space. Featured Image

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces a new exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational

– FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA – – Junshi Biosciences and Coherus are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC